DOCSLIB.ORG

Lot Lists of Pharmacopoeias EP, EPISA, ICRS, USP, BP June 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lot Lists of Pharmacopoeias EP, EPISA, ICRS, USP, BP June 2016 Lot lists of Pharmacopoeias EP, EPISA, ICRS, USP, BP June 2016 New: LGCon Standards LinkedIn Pharma Dear user, LGC Standards created this pharmacopoeial lot list for you from actual data from the Pharmacopoeais and correct at the time of production. We retained all spelling and information as provided by the Pharmacopoeias. The list was compiled with caution, however errors in this list may be possible, and LGC Standards is not responsible for any consequences as a result of these errors, may it be errors in the original Pharmacopoeia data, or from LGC Standards during compilation of this list. For any questions or orders please contact your local LGC office. You will find all contact details on the last page of this list. Alternatively, you can browse and buy pharmaceutical refer- ence materials online at www.lgcstandards.com. Stay connected via LinkedIn (LGC Standards Pharma) or Twitter @LGCStdsPharma Kind regards Your LGC Standards Team LGC Standards, Queens Road, Teddington, Middlesex, TW11 0LY, United Kingdom Tel.: +44 (0)20 8943 8480, Fax: +44 (0)20 8943 7554 E-Mail: [email protected] Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001689 Immunoglobulin (anti-A, anti-B antibodies test) Negative control BRP 1 50 mg EPY0001756 Exemestane for system suitability 1 10 mg EPY0001561 Abacavir sulfate 1 20 mg EPY0001552 Abacavir for peak identification 1 10 mg EPY0001551 Abacavir for system suitability 1 10 mg EPY0000055 Acamprosate calcium - reference spectrum 1 n/a EPY0000116 Acamprosate impurity A 1 50 mg EPY0000500 Acarbose 3 100 mg EPY0000354 Acarbose for identification 1 10 mg EPY0000427 Acarbose for peak identification 3 20 mg EPA0040000 Acebutolol hydrochloride 1 50 mg EPY0000359 Acebutolol impurity B 2 10 mg EPY0000127 Acebutolol impurity C 1 20 mg EPY0000128 Acebutolol impurity I 2 0.004 mg EPY0000056 Aceclofenac - reference spectrum 1 n/a EPY0000085 Aceclofenac impurity F 2 15 mg EPY0000086 Aceclofenac impurity H 1 10 mg EPY0001094 Aceclofenac for peak identification 1 10 mg EPY0000810 Acemetacin 1 100 mg EPY0000811 Acemetacin impurity A 1 10 mg EPY0000842 Acemetacin impurity mixture 1 0.06 mg EPA0070000 Acesulfame potassium 2 50 mg EPA0070020 Acesulfame potassium impurity B 4 15 mg EPA0100000 Acetazolamide 1 100 mg EPY0001084 Acetazolamide for system suitability 2 0.0068 mg EPY0000002 Acetylcholine chloride 1 50 mg EPA0150000 Acetylcysteine 3 50 mg EPA0152000 Acetylcysteine impurity C 11 10 mg EPA0153000 Acetylcysteine impurity D 6 10 mg EPY0000565 ß-Acetyldigoxin 2 50 mg EPY0000642 ß-Acetyldigoxin for peak identification 1 10 mg Follow LGC Standards Pharma on LinkedIn and June 2016 Twitter @LGCStdsPharma Pharmaceutical Lot List - NL Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPA0200000 Acetylsalicylic acid 4 15 mg 16/06/2016 EPY0001460 Acetylsalicylic acid for peak identification 3 10.3 mg New batch! EPY0001462 Acetylsulfadiazine 1 0.002 mg EPA0208000 N-Acetyltryptophan 2 125 mg EPA0202000 N-Acetyltyrosine 1 200 mg EPY0000693 Acholeplasma laidlawii BRP 1 1 ml EPA0220000 Aciclovir 3 75 mg EPY0001271 Aciclovir for peak identification 1 4 0.3 mg EPY0001269 Aciclovir for peak identification 2 4 0.004 mg EPY0001264 Aciclovir for system suitability 1 10 mg EPA0225000 Acitretin 2 100 mg EPY0001463 Actaea racemosa HRS 1 1200 mg EPY0001543 Actaea racemosa for assay CRS 1 300 mg EPY0001464 Actaea racemosa dry extract for system suitability HRS 1 1200 mg EPY0001121 Adapalene 1 100 mg EPY0001120 Adapalene impurity C 3 6 mg EPY0001119 Adapalene for peak identification 2 2.022 mg EPA0230000 Adenine 2 50 mg EPA0230200 Adenosine 1 50 mg EPY0000110 Adipic acid 1 50 mg EPY0000882 Adrenaline 1 5 mg EPY0000740 Adrenaline impurity mixture 3 0.0045 mg EPY0000883 Adrenaline with impurity F 1 10 mg EPA0300000 Adrenaline tartrate 6 100 mg EPY0000707 Adrenaline tartrate with impurity A 1 15 mg EPY0001724 Agnus castus fruit dry extract 1 350 mg EPA0325000 Alanine 3 60 mg EPA0325100 Albendazole 2 50 mg EPA0325200 Alcuronium chloride 2 50 mg EPA0325450 Alfacalcidol 9 5 mg EPY0001601 Alfacalcidol for system suitability 1 2.5 mg Follow LGC Standards Pharma on LinkedIn and June 2016 Twitter @LGCStdsPharma Pharmaceutical Lot List - NL Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPA0325451 Alfacalcidol - reference spectrum 1 n/a EPA1225000 Alfadex 3 150 mg EPA0325500 Alfentanil hydrochloride - reference spectrum 1 n/a EPY0000832 Alfuzosin for system suitability 1 10 mg EPA0325800 Alfuzosin hydrochloride 2 10 mg EPY0001583 Alimemazine hemitartrate 1 15 mg EPY0001581 Alimemazine for system suitability 1 5 mg EPA0349000 Allantoin 1 60 mg EPA0350000 Allopurinol 3 100 mg EPA0350010 Allopurinol impurity A 2 10 mg EPA0350020 Allopurinol impurity B 3 10 mg EPA0350030 Allopurinol impurity C 3 10 mg EPA0350040 Allopurinol impurity D 4 15 mg EPA0350050 Allopurinol impurity E 1 20 mg EPA0351000 Allylstrychnine bromide 1 10 mg EPY0000235 Almagate 2 50 mg EPY0000255 Almagate - reference spectrum 1 n/a EPA0357000 Alprazolam - * psy 2 100 mg EPA0360000 Alprenolol hydrochloride 1 100 mg EPY0000054 Alprostadil 3 25 mg EPY0000606 Altizide 2 150 mg EPY0000843 Altizide impurity B 1 15 mg EPY0000687 Alverine citrate 1 5 mg EPY0001819 Alverine impurity C 1 0.125 mg EPY0000607 Alverine impurity D 1 10 mg EPY0000595 Alverine for peak identification 2 0.125 mg EPA0363000 Amantadine hydrochloride 1 100 mg EPA0363700 Ambroxol hydrochloride 3 125 mg EPA0900000 Amfetamine sulfate - reference spectrum 1 n/a EPA0365000 Amidotrizoic acid dihydrate 1 100 mg EPY0001461 Amidotrizoic acid for system suitability 1 0.08 mg Follow LGC Standards Pharma on LinkedIn and June 2016 Twitter @LGCStdsPharma Pharmaceutical Lot List - NL Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPA0368000 Amikacin 3 200 mg EPY0001467 Amikacin impurity I 1 20 mg EPY0001117 Amikacin for system suitability 3 10 mg EPA0365900 Amikacin sulfate 3 200 mg EPA0370000 Amiloride hydrochloride 2 100 mg EPY0000020 Amiloride impurity A 3 20 mg EPY0000173 4-Aminobenzoic acid 2 60 mg EPA0420000 Aminocaproic acid 1 50 mg EPA0460000 7-Aminodesacetoxycephalosporanic acid 2 20 mg EPA0496000 Aminoglutethimide 1 125 mg EPA0496005 Aminoglutethimide impurity A 1 20 mg EPA0496020 Aminoglutethimide impurity D 1 10 mg EPA0575000 Amiodarone hydrochloride 3 100 mg EPY0000129 Amiodarone impurity D 3 20 mg EPY0000130 Amiodarone impurity E 3 20 mg EPA0590000 Amisulpride 2 10 mg EPY0001534 Amisulpride for system suitability 1 1.0015 mg EPY0000563 Amitriptyline hydrochloride 1 10 mg EPY0000049 Amlodipine besilate 4 150 mg EPY0001068 Amlodipine impurity A 3 15 mg EPY0001069 Amlodipine impurity B 2 15 mg EPY0001070 Amlodipine impurity G 3 10 mg 14/06/2016 EPY0001067 Amlodipine for peak identification 3 15 mg New batch! EPY0000302 Ammonio methacrylate copolymer(type A) - reference spectrum 1 n/a EPY0000303 Ammonio methacrylate copolymer(type B) - reference spectrum 1 n/a EPA0650000 Amobarbital - * psy 1 500 mg EPA0700000 Amobarbital sodium - * psy 1 500 mg EPY0001794 Amorolfine Hydrochloride 1 10 mg EPY0001795 Amorolfine for system suitability 1 10 mg EPA0800000 Amoxicillin trihydrate 5 200 mg EPY0001521 Amoxicillin trihydrate for performance verification 1 5000 mg Follow LGC Standards Pharma on LinkedIn and June 2016 Twitter @LGCStdsPharma Pharmaceutical Lot List - NL Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0000005 Amphotericin B 5 100 mg EPY0001361 Amphotericin B for microbiological assay 1 100 mg EPY0001014 Amphotericin B for peak identification 2 10 mg EPA1000000 Ampicillin (anhydrous) 5 220 mg EPA1100000 Ampicillin trihydrate 2 150 mg EPY0001244 Amylmetacresol 1 285 mg EPY0001245 Amylmetacresol for peak identification 1 10 mg EPY0001522 Anastrozole 1 100 mg EPY0001531 Anastrozole impurity E 1 10 mg EPY0001753 Anemarrhena rhizome for system suitability HRS 1 150 mg EPY0001386 Angelica dahurica root HRS 1 160 mg EPY0001385 Angelica pubescens root 1 500 mg EPA1200000 Anhydrotetracycline hydrochloride 4 15 mg EPY0001466 Anhydrous Docetaxel 1 15 mg EPA1210000 Antazoline hydrochloride 1 50 mg EPY0001777 Apigenin 7-glucoside 1 25 mg EPY0001465 Apomorphine hydrochloride hemihydrate 1 15 mg EPY0001471 Apomorphine impurity B (morphine sulfate) * - narc 1 40 mg EPA1220000 Alpha-apo-oxytetracycline 5 20 mg EPA1230000 Beta-apo-oxytetracycline 5 20 mg EPY0001154 Aprotinin for system suitability 1 2.7 mg EPA1250000 Aprotinin solution BRP 4 0.5 mL EPA1269000 L-Arabinitol 2 10 mg EPY0000806 Arbutin 2 110 mg EPA1270000 Arginine 4 60 mg EPY0000304 Arginine aspartate 1 20 mg EPA1271000 Arginine hydrochloride 3 60 mg EPY0001649 Aripiprazole 1 170 mg EPY0001650 Aripiprazole impurity F 2 15 mg EPY0001323 Aristolochia 1 140 mg EPY0001185 Aristolochic acid I 1 11 mg Follow LGC Standards Pharma on LinkedIn and June 2016 Twitter @LGCStdsPharma Pharmaceutical Lot List - NL Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001175 Aristolochic acid for system suitability 1 1 mg EPY0000079 Articaine hydrochloride 3 200 mg EPY0000080 Articaine impurity A 3 25 mg EPY0000081 Articaine impurity E 2 10 mg EPY0001091 Artichoke leaf dry extract HRS 1 60 mg EPA1300000 Ascorbic acid 4 100 mg EPY0001024 Ascorbic acid impurity C 3 20 mg EPY0001170 Ascorbic acid impurity D 2 10 mg EPY0000800 Ascorbyl palmitate 1 10 mg EPY0001206 Asiaticoside 1 40 mg EPY0000305 Asparagine monohydrate 1 60 mg EPA1320000 Aspartame 2 40 mg EPA1321000 Aspartame impurity A 4 10 mg EPA1330000 Aspartic acid
Load more

Recommended publications
  • Fluorometholone Ophthalmic Suspension 0.1% W/V Corticosteroid Anti-Inflammatory
    PRODUCT MONOGRAPH PrFML® Fluorometholone Ophthalmic Suspension 0.1% w/v Corticosteroid Anti-Inflammatory Allergan Inc. Date of Preparation: Markham, ON October 30, 1972 L6G 0B5 Date of Revision: May 2, 2018 Submission Control No: 214474 Page 1 of 12 NAME OF DRUG Pr ® FML Fluorometholone Ophthalmic Suspension 0.1% w/v THERAPEUTIC CLASSIFICATION Topical corticosteroid ACTIONS Corticosteroids inhibit the inflammatory response to a variety of inciting agents of a mechanical, chemical and immunological nature. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, phagocytic activity, capillary proliferation, fibroblast proliferation, deposition of collagen and scar formation associated with inflammation. Corticosteroids are thought to act by controlling the rate of synthesis of proteins. Corticosteroids and their derivatives are capable of producing a rise in intraocular pressure. INDICATIONS FML® (fluorometholone ophthalmic suspension 0.1% w/v) is indicated for the treatment of steroid- responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. CONTRAINDICATIONS FML® is contraindicated in: Superficial (or epithelial) herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and other viral diseases of the cornea and conjunctiva. Fungal diseases of ocular structures. Mycobacterial infections of the eye (e.g., Tuberculosis of the eye). Acute untreated infections of the eye. Hypersensitivity to the constituents of this medication (for a listing of ingredients, see PHARMACEUTICAL INFORMATION), or hypersensitivity to other corticosteroids. Page 2 of 12 WARNINGS Use of topical corticosteroids may cause increased intraocular pressure (IOP) in certain individuals. It is necessary that the IOP be checked frequently in patients with a history of glaucoma. Use of corticosteroids may prolong the course and may exacerbate the severity of many viral eye infections (including herpes simplex).
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Penetration of Synthetic Corticosteroids Into Human Aqueous Humour
    Eye (1990) 4, 526--530 Penetration of Synthetic Corticosteroids into Human Aqueous Humour C. N. 1. McGHEE,1.3 D. G. WATSON, 3 1. M. MIDGLEY, 3 M. 1. NOBLE, 2 G. N. DUTTON, z A. I. FERNl Glasgow Summary The penetration of prednisolone acetate (1%) and fluorometholone alcohol (0.1%) into human aqueous humour following topical application was determined using the very sensitive and specific technique of Gas Chromatography with Mass Spec­ trometry (GCMS). Prednisolone acetate afforded peak mean concentrations of 669.9 ng/ml within two hours and levels of 28.6 ng/ml in aqueous humour were detected almost 24 hours post application. The peak aqueous humour level of flu­ orometholone was S.lng/ml. The results are compared and contrasted with the absorption of dexamethasone alcohol (0.1%), betamethasone sodium phosphate (0.1 %) and prednisolone sodium phosphate (0.5%) into human aqueous humour. Topical corticosteroid preparations have been prednisolone acetate (1.0%) and fluorometh­ used widely in ophthalmology since the early alone alcohol (0.1 %) (preliminary results) 1960s and over the last 10 years the choice of into the aqueous humour of patients under­ preparations has become larger and more going elective cataract surgery. varied. Unfortunately, data on the intraocular penetration of these steroids in humans has SUbjects and Methods not paralleled the expansion in the number of Patients who were scheduled to undergo rou­ available preparations; indeed until recently, tine cataract surgery were recruited to the estimation of intraocular penetration has study and informed consent was obtained in been reliant upon extrapolation of data from all cases (n=88), Patients with corneal disease animal models (see Watson et ai., 1988, for or inflammatory ocular conditions which bibliography).
    [Show full text]
  • Electronic Supplementary Information: Solid-Phase Extraction As Sample Preparation of Water Samples for Cell-Based and Other in Vitro Bioassays
    Electronic Supplementary Material (ESI) for Environmental Science: Processes & Impacts. This journal is © The Royal Society of Chemistry 2018 Electronic Supplementary Information: Solid-phase extraction as sample preparation of water samples for cell-based and other in vitro bioassays Peta A. Neale, Werner Brack, Selim Aїt-Aїssa, Wibke Busch, Juliane Hollender, Martin Krauss, Emmanuelle Maillot-Maréchal, Nicole A. Munz, Rita Schlichting, Tobias Schulze, Bernadette Vogler, Beate I. Escher Table S1: Studies that have determined the BEQbio,extract/BEQchem,extract ratio to assess chemical SPE recovery expressed as effect in a water matrix. Table S2: Studies that have determined the BEQbio,extract/BEQchem,nominal ratio to assess chemical SPE recovery expressed as effect in a water matrix. Table S3: List of the 579 chemicals spiked into Wormsgraben water (provided in Excel file). Section S1: Chemical analysis of LVSPE recovery experiment. Section S2: Chemical analysis of multi-layer SPE recovery experiments. Table S4: Measured concentration in ng/L in the water extract and water + mix extract, as well as the nominal spiked concentration in ng/L and the fraction of each chemical recovered by LVSPE 1 (frecovery,i). frecovery,i is also provided for Schulze et al. (provided in Excel file). Table S5: Results for background, recovery and calibration samples for calculation of frecovery for multi-layer SPE cartridges (provided in Excel file). Figure S1: Ratio of frecovery,i for LVSPE from the current study and frecovery,i for LVSPE (HR-X only) 1 from Schulze et al. and ratio of frecovery,i for LVSPE and frecovery,i for multi-layer SPE cartridges (both measured in current study).
    [Show full text]
  • Research Publications by DISTINCTIONS Any Scientist of Pakistan in Last 10 Year and SERVICES  Secretary General, the Chemical Society of Pakistan
    CV and List of Publications PROF. DR. MUHAMMAD IQBAL CHOUDHARY (Hilal-e-Imtiaz, Sitara-e-Imtiaz, Tamgha-ei-Imtiaz) International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry, Dr. Panjwani Center for Molecular Medicine and Drug Research) University of Karachi, Karachi-75270 Pakistan Tel: (92-21) 34824924, 34824925 Fax: 34819018, 34819019 E-mail: [email protected] Web Page: www.iccs.edu Biodata and List of Publications Pag No. 2 MUHAMMAD IQBAL CHOUDHARY (Hilal-e-Imtiaz, Sitara-e-Imtiaz, Tamgha-e-Imtiaz) D-131, Phase II, D. O. H. S., Malir Cant., Karachi-75270, Pakistan Ph.: 92-21-4901110 MAILING INTERNATIONAL CENTER FOR CHEMICAL AND BIOLOGICAL SCIENCES ADDRESS (H. E. J. Research Institute of Chemistry Dr. Panjwani Center for Molecular Medicine and Drug Research) University of Karachi Karachi-74270, Pakistan Tel: (92-21) 34824924-5 Fax: (92-21) 34819018-9 Email: [email protected] Web: www.iccs.edu DATE OF BIRTH September 11, 1959 (Karachi, Pakistan) EDUCATION Doctor of Science (D.Sc.) (University of Karachi ) 2005 Ph.D. (Organic Chemistry) 1987 H. E. J. Research Institute of Chemistry University of Karachi, Karachi-75270, Pakistan Thesis Title: "The Isolation and Structural Studies on Some Medicinal Plants of Pakistan, Buxus papillosa, Catharanthus roseus, and Cissampelos pareira." M.Sc. (Organic Chemistry) 1983 University of Karachi, Karachi-75270, Pakistan B.Sc. (Chemistry, Biochemistry, Botany) 1980 University of Karachi, Karachi-75270, Pakistan AWARDS & Declared as the top most scientist (Number 1) among 1,650 HONORS scientists of Pakistan in all disciplines / fields of science and technology (year 2012) by the Pakistan Council for Science and Technology (Ministry of Science and Technology), Pakistan.
    [Show full text]
  • The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral 2 replication-transcription complex in culture cells 3 4 Shutoku Matsuyamaa#, Miyuki Kawasea, Naganori Naoa, Kazuya Shiratoa, Makoto Ujikeb, Wataru 5 Kamitanic, Masayuki Shimojimad, and Shuetsu Fukushid 6 7 aDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan 8 bFaculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan 9 cDepartment of Infectious Diseases and Host Defense, Gunma University Graduate School of 10 Medicine, Gunma, Japan 11 dDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 12 13 Running Head: Ciclesonide blocks SARS-CoV-2 replication 14 15 #Address correspondence to Shutoku Matsuyama, [email protected] 16 17 Word count: Abstract 149, Text 3,016 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 We screened steroid compounds to obtain a drug expected to block host inflammatory responses and 20 MERS-CoV replication. Ciclesonide, an inhaled corticosteroid, suppressed replication of MERS-CoV 21 and other coronaviruses, including SARS-CoV-2, the cause of COVID-19, in cultured cells. The 22 effective concentration (EC90) of ciclesonide for SARS-CoV-2 in differentiated human bronchial 23 tracheal epithelial cells was 0.55 μM.
    [Show full text]
  • Quantitative High-Throughput Profiling of Environmental Chemicals and Drugs That Modulate Farnesoid X Receptor
    OPEN Quantitative High-Throughput Profiling of SUBJECT AREAS: Environmental Chemicals and Drugs that SCREENING SMALL MOLECULES Modulate Farnesoid X Receptor Chia-Wen Hsu1, Jinghua Zhao1, Ruili Huang1, Jui-Hua Hsieh2, Jon Hamm3, Xiaoqing Chang3, Keith Houck4 Received & Menghang Xia1 27 June 2014 Accepted 1National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, 2Division of the National 29 August 2014 Toxicology Program, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 3Integrated Laboratory Systems, Inc., Morrisville, NC, 4U.S. Environmental Protection Agency, Research Triangle Park, NC. Published 26 September 2014 The farnesoid X receptor (FXR) regulates the homeostasis of bile acids, lipids, and glucose. Because endogenous chemicals bind and activate FXR, it is important to examine which xenobiotic compounds Correspondence and would disrupt normal receptor function. We used a cell-based human FXR b-lactamase (Bla) reporter gene assay to profile the Tox21 10K compound collection of environmental chemicals and drugs. requests for materials Structure-activity relationships of FXR-active compounds revealed by this screening were then compared should be addressed to against the androgen receptor, estrogen receptor a, peroxisome proliferator-activated receptors d and c, and M.X. ([email protected]. the vitamin D receptor. We identified several FXR-active structural classes including anthracyclines, gov) benzimidazoles, dihydropyridines, pyrethroids, retinoic acids, and vinca alkaloids. Microtubule inhibitors potently decreased FXR reporter gene activity. Pyrethroids specifically antagonized FXR transactivation. Anthracyclines affected reporter activity in all tested assays, suggesting non-specific activity. These results provide important information to prioritize chemicals for further investigation, and suggest possible modes of action of compounds in FXR signaling.
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME FML® 0.1% w/v eye drops 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Fluorometholone 1 mg/mL (0.1% w/v) For the full list of excipients, see Section 6.1. 3. PHARMACEUTICAL FORM A topical anti-inflammatory glucosteroid ophthalmic suspension. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications For steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. 4.2 Dose and method of administration Bottle should be shaken before use. 1 to 2 drops instilled into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosage may be safely increased to 2 drops every hour. Care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of applications. In order to minimise systemic absorption of FML® eye drops, apply pressure to the tear duct immediately following administration of the drug. Use in children: Safety and effectiveness have not been demonstrated in children under 2 years of age. 4.3 Contraindications FML® is contraindicated in patients with: acute superficial (or epithelial) Herpes simplex keratitis (dendritic keratitis), fungal diseases of ocular structures, vaccinia, varicella, mycobacterial infection of the eye and most other viral diseases of the cornea and conjunctiva, tuberculosis of the eye, hypersensitivity to the active substance or to any of the excipients listed in section 6.1. FML® (fluorometholone) 0.1% w/v eye drops Data sheet Version 5.0 Page 1 of 6 4.4 Special warnings and precautions for use Steroid medication in the treatment of patients with a history of Herpes simplex keratitis requires great caution.
    [Show full text]
  • Ophthalmic Anti-Inflammatories Review 06/10/2010
    Ophthalmic Anti-Inflammatories Review 06/10/2010 Copyright © 2004 - 2010 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 10101 Alliance Road, Ste 201 Cincinnati, Ohio 45242 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is
    [Show full text]
  • USP Reference Standards Catalog
    Last Updated On: January 6, 2016 USP Reference Standards Catalog Catalog # Description Current Lot Previous Lot CAS # NDC # Unit Price Special Restriction 1000408 Abacavir Sulfate R028L0 F1L487 (12/16) 188062-50-2 $222.00 (200 mg) 1000419 Abacavir Sulfate F0G248 188062-50-2 $692.00 Racemic (20 mg) (4-[2-amino-6-(cyclo propylamino)-9H-pur in-9yl]-2-cyclopenten e-1-methanol sulfate (2:1)) 1000420 Abacavir Related F1L311 F0H284 (10/13) 124752-25-6 $692.00 Compound A (20 mg) ([4-(2,6-diamino-9H- purin-9-yl)cyclopent- 2-enyl]methanol) 1000437 Abacavir Related F0M143 N/A $692.00 Compound D (20 mg) (N6-Cyclopropyl-9-{( 1R,4S)-4-[(2,5-diami no-6-chlorpyrimidin- 4-yloxy)methyl] cyclopent-2-enyl}-9H -purine-2,6-diamine) 1000441 Abacavir Related F1L318 F0H283 (10/13) N/A $692.00 Compound B (20 mg) ([4-(2,5-diamino-6-c Page 1 Last Updated On: January 6, 2016 USP Reference Standards Catalog Catalog # Description Current Lot Previous Lot CAS # NDC # Unit Price Special Restriction hloropyrimidin-4-yla mino)cyclopent-2-en yl]methanol) 1000452 Abacavir Related F1L322 F0H285 (09/13) 172015-79-1 $692.00 Compound C (20 mg) ([(1S,4R)-4-(2-amino -6-chloro-9H-purin-9 -yl)cyclopent-2-enyl] methanol hydrochloride) 1000485 Abacavir Related R039P0 F0J094 (11/16) N/A $692.00 Compounds Mixture (15 mg) 1000496 Abacavir F0J102 N/A $692.00 Stereoisomers Mixture (15 mg) 1000500 Abacavir System F0J097 N/A $692.00 Suitability Mixture (15 mg) 1000521 Acarbose (200 mg) F0M160 56180-94-0 $222.00 (COLD SHIPMENT REQUIRED) 1000532 Acarbose System F0L204 N/A $692.00 Suitability
    [Show full text]
  • Small Molecules in Solution Has Rarely Been Reported, However, As a General Guide We Recommend Storage in DMSO at -20°C
    (Z)-Guggulsterone Small Molecules Retinoic acid receptor (RAR) pathway inhibitor; Inhibits farnesoid X receptor (FXR) Catalog # 73702 1 mg Product Description (Z)-Guggulsterone is a plant steroid found in the resin of the guggul plant Commiphora mukul that acts as a selective antagonist of farnesoid X receptor (FXR; Cui et al.). It decreases chenodeoxycholic acid (CDCA)-induced FXR activation (IC ₅₀ = 10 µM) in the presence of 100 µM CDCA (Urizar et al.; Cui et al.). Molecular Name: (Z)-Guggulsterone Alternative Names: Not applicable CAS Number: 39025-23-5 Chemical Formula: C₂₁H₂₈O₂ Molecular Weight: 312.5 g/mol Purity: ≥ 95% Chemical Name: (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15- decahydrocyclopenta[a]phenanthrene-3,16-dione Structure: Properties Physical Appearance: A crystalline solid Storage: Product stable at -20°C as supplied. Protect product from prolonged exposure to light. For long-term storage store with a desiccant. For product expiry date, please contact [email protected]. Solubility: · DMSO ≤ 800 µM · Absolute ethanol ≤ 3.2 µM · DMF ≤ 30 mM For example, to prepare a 10 mM stock solution in DMF, resuspend 1 mg in 320 μL of DMF. Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported, however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application. Compound has low solubility in aqueous media.
    [Show full text]
  • Guggulsterones and Levels
    Cholesterol, Guggulsterones and levels. Because normal levels of serum lipids, Bile Production including cholesterol, are supported by increased circulating thyroid hormones, it is believed guggul Much of the cholesterol made by your liver is uti- Guggulsterones works by stimulating the thyroid gland, in addition lized to create bile, a substance used in digestion to its effects on bile production. to emulsify fats. Because excess cholesterol and triglycerides are excreted from our bodies in the Clinically Effective Dosage form of bile, it is important to support the liver’s bile-producing mechanism. According to several clinical studies, the amount of guggulsterones used to maintain Natural Support for Research shows that certain guggul compounds— normal cholesterol levels is 75 mg per day, guggulsterones—help maintain cholesterol levels when taken with a diet low in saturated fats. Cholesterol Health in the normal range and act at the farnesoid X This is the daily dose delivered by SOURCE receptor (FXR) to promote bile production. NATURALS GUGGULSTERONES. Guggulsterones appear to be farnesoid X receptor (FXR) antagonists. FXR is a bile acid receptor. If A Wellness Revolution in FXR is activated, this results in down-regulation Cardiovascular Care of the amount of bile acids produced by the liver. Bile is made out of cholesterol, which gets used up At a time when our cardiovascular health faces when bile is produced. When bile levels are high, numerous lifestyle challenges, research into the the production of more bile is slowed through remarkable heart-supportive properties of the oday’s lifestyle, with its high-fat, processed food diet, lack of exercise, and negative feedback of the FXR pathway.
    [Show full text]